Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab

[cafead]

via Clinical-stage biopharma company F-star Therapeutics announced a new partnership with Janssen Biotech on Wednesday, only one month after presenting an optimistic trial-in-progress update to the public on its tetravalent dual T-cell agonist FS120 at the European Society for Medical Oncology 2021 Conference.

article source